$0.81
1.76% yesterday
Nasdaq, Jun 13, 10:00 pm CET
ISIN
US8112921015
Symbol
SCYX
Reports
Quarter | Annual
Index
NASDAQ Composite
Sector
Health
Industry
Pharmaceuticals

SCYNEXIS, Inc. Stock News

Neutral
GlobeNewsWire
●
17 days ago
SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study
JERSEY CITY, N.J., May 28, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that patient dosing has resumed in the Phase 3 MARIO study, which is an innovative study to investigate oral ibrexafungerp as a potential step-down antifungal therapy f...
Neutral
GlobeNewsWire
●
3 months ago
SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update
JERSEY CITY, N.J., March 12, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today reported financial results for the year ended December 31, 2024.

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now
The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today